Eric Lefkosky: Changing the Way We Treat Cancer


Dartmouth Study Finds Three New Cancer Biomarkers

There are many risk factors that aid in the development of lung cancer. Yafang Li, PhD, recently led a research team to explain how the interactions of gene-smoking have a huge part in creating cancer in the lungs. The study contained three novel SNPs, otherwise known as single-nucleotide polymorphisms, that were potential signs for someone that needed to get screening and intervention for lung cancer. The findings from the experiment have all been published in Carcinogensis. This study was just done with a Caucasian population, but the team wants to conduct the study on different populations in the future.

Eric Lefkofsky

Eric Lefkofsky is the co-founder of Tempus, which is a company that created an operating system to help treat cancer. The company specializes in treatment for patients that have lung, breast, and pancreatic cancer. There are about 29 Employees that are working with Lefkofsky in the company. Depending on how well the company does, Lefkofsky and his staff hope to add more treatment for different types of cancer. Lefkofsky also co-founded Lightbank which is a venture fund used to investigate disruptive technologies. Lefkofsky has co-founded multiplies other ventures such as Echo Global Logistic, Uptake Technologies, and Mediaocean.

Lefkofsky and his wife created the Lefkofskly Family Foundation in 2006. This foundation serves to further multiple initiatives in the communities of Chicago. Lefkofsky is on the board of the Lurie Children’s Hospital of Chicago, The Museum of Science and Industry, and The Art Institute of Chicago.

Eric Lefkofsky is also a part-time professor at the University of Chicago. He has also written and published work within his field. His book, Accelerated Disruption is one of his most acclaimed works. Lefkofsky is an alumnus of the University of Michigan. He also attended the University of Michigan Law School to receive his Juris Doctor.

To know more click here